• +1-646-491-9876
    • +91-20-67278686

    Search

    Optic Neuropathy - Pipeline Review, H1 2017

    Optic Neuropathy - Pipeline Review, H1 2017

    • Report Code ID: RW0001709439
    • Category Pharmaceuticals
    • No. of Pages 48
    • Publication Month Mar-17
    • Publisher Name Global Markets Direct
    Optic Neuropathy - Pipeline Review, H1 2017

    Summary

    Publisher's latest Pharmaceutical and Healthcare disease pipeline guide Optic Neuropathy - Pipeline Review, H1 2017, provides an overview of the Optic Neuropathy (Ophthalmology) pipeline landscape.

    Optic neuropathy is an inherited form of vision loss. Symptoms include eye pain or discomfort, numbness, tingling and clouding of vision. Predisposing factors include age, tobacco smoke, alcohol, cancer treating drugs, stress related chemicals, some antibiotics and cyanogens.

    Report Highlights

    Publisher's Pharmaceutical and Healthcare latest pipeline guide Optic Neuropathy - Pipeline Review, H1 2017, provides comprehensive information on the therapeutics under development for Optic Neuropathy (Ophthalmology) , complete with analysis by stage of development, drug target, mechanism of action (MoA) , route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

    The Optic Neuropathy (Ophthalmology) pipeline guide also reviews of key players involved in therapeutic development for Optic Neuropathy and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I and Preclinical stages are 1, 1, 1 and 4 respectively. Similarly, the Universities portfolio in Preclinical and Discovery stages comprises 3 and 2 molecules, respectively.

    Optic Neuropathy (Ophthalmology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Publisher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

    Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

    Scope

    - The pipeline guide provides a snapshot of the global therapeutic landscape of Optic Neuropathy (Ophthalmology) .
    - The pipeline guide reviews pipeline therapeutics for Optic Neuropathy (Ophthalmology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
    - The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
    - The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
    - The pipeline guide reviews key companies involved in Optic Neuropathy (Ophthalmology) therapeutics and enlists all their major and minor projects.
    - The pipeline guide evaluates Optic Neuropathy (Ophthalmology) therapeutics based on mechanism of action (MoA) , drug target, route of administration (RoA) and molecule type.
    - The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
    - The pipeline guide reviews latest news related to pipeline therapeutics for Optic Neuropathy (Ophthalmology)

    Reasons to buy

    - Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
    - Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
    - Find and recognize significant and varied types of therapeutics under development for Optic Neuropathy (Ophthalmology) .
    - Classify potential new clients or partners in the target demographic.
    - Develop tactical initiatives by understanding the focus areas of leading companies.
    - Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
    - Formulate corrective measures for pipeline projects by understanding Optic Neuropathy (Ophthalmology) pipeline depth and focus of Indication therapeutics.
    - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
    - Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
    Table of Contents
    List of Tables
    List of Figures
    Introduction
    Publisher Report Coverage
    Optic Neuropathy - Overview
    Optic Neuropathy - Therapeutics Development
    Pipeline Overview
    Pipeline by Companies
    Pipeline by Universities/Institutes
    Products under Development by Companies
    Products under Development by Universities/Institutes
    Optic Neuropathy - Therapeutics Assessment
    Assessment by Target
    Assessment by Mechanism of Action
    Assessment by Route of Administration
    Assessment by Molecule Type
    Optic Neuropathy - Companies Involved in Therapeutics Development
    Amgen Inc
    BioAxone BioSciences Inc
    Inotek Pharmaceuticals Corp
    Ironwood Pharmaceuticals Inc
    PharmatrophiX Inc
    Quark Pharmaceuticals Inc
    Regenera Pharma Ltd
    Optic Neuropathy - Drug Profiles
    BA-240 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    IWP-953 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    LM-22A4 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    Monoclonal Antibodies to Inhibit Sema3A for Glaucoma and Optic Neuropathy - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    NT-501 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    QPI-1007 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    RPh-201 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    Small Molecule to Inhibit Sema3A for Glaucoma and Optic Neuropathy - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    Small Molecules for CNS Disorders and Ophthalmology - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    Small Molecules for Neurological and Ophthalmological Diseases - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    Synthetic Peptide to Inhibit Connexin 43 for Optic Neuropathy - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    trabodenoson - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    Optic Neuropathy - Dormant Projects
    Optic Neuropathy - Product Development Milestones
    Featured News & Press Releases
    Apr 26, 2016: Inotek Pharmaceuticals Announces Poster Presentations on Trabodenoson at the ARVO 2016 Annual Meeting
    Feb 28, 2014: Regenera Pharma has been initiated the Phase IIa study in patients with chronic Ischemic Optic Neuropathy
    Sep 18, 2012: Neurotech Pharmaceuticals Provides Update On NT-501
    Apr 30, 2011: Regenera Pharma received the final report of its safety study in minipigs and is moving to human studies
    Appendix
    Methodology
    Coverage
    Secondary Research
    Primary Research
    Expert Panel Validation
    Contact Us
    Disclaimer

    List of Tables

    Number of Products under Development for Optic Neuropathy, H1 2017
    Number of Products under Development by Companies, H1 2017
    Number of Products under Development by Universities/Institutes, H1 2017
    Products under Development by Companies, H1 2017
    Products under Development by Universities/Institutes, H1 2017
    Number of Products by Stage and Target, H1 2017
    Number of Products by Stage and Mechanism of Action, H1 2017
    Number of Products by Stage and Route of Administration, H1 2017
    Number of Products by Stage and Molecule Type, H1 2017
    Optic Neuropathy - Pipeline by Amgen Inc, H1 2017
    Optic Neuropathy - Pipeline by BioAxone BioSciences Inc, H1 2017
    Optic Neuropathy - Pipeline by Inotek Pharmaceuticals Corp, H1 2017
    Optic Neuropathy - Pipeline by Ironwood Pharmaceuticals Inc, H1 2017
    Optic Neuropathy - Pipeline by PharmatrophiX Inc, H1 2017
    Optic Neuropathy - Pipeline by Quark Pharmaceuticals Inc, H1 2017
    Optic Neuropathy - Pipeline by Regenera Pharma Ltd, H1 2017
    Optic Neuropathy - Dormant Projects, H1 2017

    List of Figures

    Number of Products under Development for Optic Neuropathy, H1 2017
    Number of Products under Development by Companies, H1 2017
    Number of Products under Development by Universities/Institutes, H1 2017
    Number of Products by Targets, H1 2017
    Number of Products by Stage and Targets, H1 2017
    Number of Products by Mechanism of Actions, H1 2017
    Number of Products by Stage and Mechanism of Actions, H1 2017
    Number of Products by Routes of Administration, H1 2017
    Number of Products by Stage and Routes of Administration, H1 2017
    Number of Products by Molecule Types, H1 2017
    Number of Products by Stage and Molecule Types, H1 2017
    Amgen Inc
    BioAxone BioSciences Inc
    Inotek Pharmaceuticals Corp
    Ironwood Pharmaceuticals Inc
    PharmatrophiX Inc
    Quark Pharmaceuticals Inc
    Regenera Pharma Ltd

    Request for Sample

    Report Url http://www.reportsweb.com//optic-neuropathy-pipeline-review-h1-2017&type=sample
    Report Name
    First Name
    Last Name
    Email
    Phone
    Company
    Job Title
    Country
    Publisher
    Report Code
    Comments
     

    Inquire before Buying

    Report Url http://www.reportsweb.com//optic-neuropathy-pipeline-review-h1-2017&type=buying
    Report Name
    First Name
    Last Name
    Email
    Phone
    Company
    Job Title
    Country
    Publisher
    Report Code
    Comments
     

    Inquire for Discount

    Report Url http://www.reportsweb.com//optic-neuropathy-pipeline-review-h1-2017&type=discount
    Report Name
    First Name
    Last Name
    Email
    Phone
    Company
    Job Title
    Country
    Publisher
    Report Code
    Comments